Learning from prostate cancer statistics

At present, increased early detection of prostate cancer appears to be the most feasible way to reduce cancer-related mortality. As a result significant efforts have been made to identify more men with curable cancer. This article reviews the role of serum prostate-specific antigen in an early detection or screening strategy and describes efforts to enhance the specificity of prostate-specific antigen testing.

Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time

Oxidative Stress Measured by Urine F2-Isoprostane Level is Associated With Prostate Cancer

Evidence to Support a Continued Stage Migration and Decrease in Prostate Cancer Specific Mortality

Bladder Cancer Incidence and Risk Factors in Men With Prostate Cancer: Results From Cancer of the Prostate Strategic Urologic Research Endeavor

MEDICAL AND SURGICAL PALLIATIVE CARE OF PATIENTS WITH UROLOGICAL MALIGNANCIES

Mass Screening for Prostate Cancer in Korea: A Population Based Study

Overuse of Imaging for Staging Low Risk Prostate Cancer

Lack of Noggin Expression by Cancer Cells Is a Determinant of the Osteoblast Response in Bone Metastases

INTERVAL AFTER PROSTATE SPECIFIC ANTIGEN TESTING AND SUBSEQUENT RISK OF INCURABLE PROSTATE CANCER

CA: A Cancer Journal for CliniciansVolume 43, Issue 2 p. 83-91 ArticleFree Access Trends in prostate cancer care in the United States, 1974–1990: Observations from the patient care evaluation studies of the American college of surgeons commission on cancer Curtis Mettlin PhD, Curtis Mettlin PhD Chief of Epidemiologie Research and Director of Cancer Control at Roswell Park Cancer Institute in Buffalo, New YorkSearch for more papers by this authorGeorge W. Jones MD, George W. Jones MD Professor of Urology at Howard University Medical School in Washington, DCSearch for more papers by this authorGerald P. Murphy MD, Gerald P. Murphy MD Chief Medical Officer of the American Cancer Society and Editor in Chief of CASearch for more papers by this author Curtis Mettlin PhD, Curtis Mettlin PhD Chief of Epidemiologie Research and Director of Cancer Control at Roswell Park Cancer Institute in Buffalo, New YorkSearch for more papers by this authorGeorge W. Jones MD, George W. Jones MD Professor of Urology at Howard University Medical School in Washington, DCSearch for more papers by this authorGerald P. Murphy MD, Gerald P. Murphy MD Chief Medical Officer of the American Cancer Society and Editor in Chief of CASearch for more papers by this author First published: March/April 1993 https://doi.org/10.3322/canjclin.43.2.83Citations: 111AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Reference 1 Boring CC, Squires TS, Tong T: Cancer Statistics: 1993. CA Cancer J Clin 1993; 43: 7– 26. 2 Murphy GP, Natarajan N, Pontes JE, et al: The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982; 127: 928– 934. 3 Schmidt JD, Mettlin CI, Natarajan N, et al: Trends in patterns of care for prostatic cancer, 1974–1983: Results of surveys by the American College of Surgeons. J Urol 1986; 136: 416– 421. 4 GD Steele, HR Menck, DP Winchester, GP Murphy (eds): National Cancer Data Base Annual Review of Patient Care: 1992. Atlanta, American Cancer Society, 1992. 5 Steele GD Jr, Winchester MD, Menck HR, Murphy GP: Clinical highlights from the National Cancer Data Base: 1993. CA Cancer J Clin 1993; 43: 71– 82. 6 Natarajan N, Mettlin C, Beart RS, Murphy GP: Design and analysis of national patterns of care surveys of the American College of Surgeons. Neoplasia 1985; 2: 5– 10. 7 Whitmore WF Jr: Hormone therapy in prostatic cancer. Amer J Med 1956; 21: 697– 713. 8 Natarajan N, Murphy GP, Mettlin C: Prostate cancer in blacks: An update from the American College of Surgeons' patterns of care studies. J Surg Oncol 1989; 40: 232– 236. 9 Burnett AL, Chan DW, Brendler CB, Walsh PC: The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. J Urol 1992; 148: 1832– 1834. 10 Mettlin C, Lee F, Drago J, et al: The American Cancer Society National Prostate Cancer Detection Project: Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949– 2958. 11 Kane RA, Littrup PJ, Babaian R, et al: Prostate-specific antigen levels in 1695 men without evidence of prostate cancer: Findings from the American Cancer Society National Prostate Cancer Detection Project. Cancer 1992; 69: 1201– 1207. 12 Babaian RJ, Mettlin C, Kane R, et al: The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography: Findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1992; 69: 1195– 1200. 13 Mettlin C, Jones GW, Averette H, et al: Defining and updating the American Cancer Society guidelines for the cancer-related checkup: Prostate and endometrial cancers. CA Cancer J Clin 1993; 43: 42– 46. Citing Literature Volume43, Issue2March/April 1993Pages 83-91 ReferencesRelatedInformation

CONTROVERSIES IN PROSTATE CANCER SCREENING

BMP7: A New Bone Metastases Prevention?

Evidence Supports a Faster Growth Rate and/or Earlier Transformation to Clinically Significant Prostate Cancer in Black Than in White American Men, and Influences Racial Progression and Mortality Disparity

Comparison of Contrast Enhanced Color Doppler Targeted Biopsy to Conventional Systematic Biopsy: Impact on Gleason Score